Uncover key drivers, emerging technologies, and competitive movements shaping the artificial intelligence (ai) in biopharmaceuticals market from 2026–2035 with trusted insights from The Business Research Company
What growth pattern is forecast for the Artificial Intelligence (AI) In Biopharmaceuticals Market size between 2026 and 2035?
The artificial intelligence (AI) in biopharmaceuticals market size has seen remarkable growth in recent years. It is projected to increase from $2.1 billion in 2025 to $2.79 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 33.0%. The expansion observed historically can be linked to factors such as the early incorporation of AI in pharmaceutical research, advancements in computational capabilities, a surge in investment within biopharmaceutical R&D, the integration of omics data, and the proliferation of cloud-based data storage.
The artificial intelligence (ai) in biopharmaceuticals market is anticipated to experience substantial growth over the upcoming years. Its valuation is forecast to climb to $8.77 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 33.1%. This expansion during the projection period is primarily driven by enhancements in machine learning algorithms, the increasing deployment of AI-enabled laboratory equipment, broader integration of predictive analytics, the rise of collaborative AI-biopharma platforms, and governmental encouragement for AI-driven healthcare initiatives. Significant developments expected throughout this period include AI-powered drug discovery, the application of predictive analytics in clinical trials, the automation of laboratory procedures, the incorporation of real-world data, and the refinement of personalized treatment strategies.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14251&type=smp
Which Drivers Are Impacting Market Performance In The Artificial Intelligence (AI) In Biopharmaceuticals Market?
The increasing incidence of chronic illnesses is anticipated to fuel the expansion of artificial intelligence (AI) in the biopharmaceuticals market in the foreseeable future. These are enduring health conditions characterized by a gradual progression, potentially lasting for many years or throughout an individual’s life. Their development is often linked to lifestyle choices, an increasing elderly demographic, genetic susceptibilities, and environmental influences. Artificial intelligence in biopharmaceuticals is increasingly being utilized for chronic disease management, given its capability to analyze extensive and varied data, discern underlying patterns, and tailor therapeutic strategies. For example, data from April 2025, provided by the Centers for Disease Control and Prevention (CDC), a US-based federal agency, indicated that in 2023, around 194 million U.S. adults, representing 76.4% of the population, reported suffering from at least one chronic ailment. Specifically, the prevalence was noted as 59.5% among young adults, 78.4% among midlife adults, and a significant 93.0% among older adults. Consequently, the expanding occurrence of chronic diseases is a primary driver for the advancement of artificial intelligence (AI) within the biopharmaceuticals market.
What Segment Types Are Examined In The Artificial Intelligence (AI) In Biopharmaceuticals Market?
The artificial intelligence (ai) in biopharmaceuticals market covered in this report is segmented –
1) By Offering: Hardware, Software, Services
2) By Deployment: Cloud, On-Premises
3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies
4) By Application: Drug Discovery, Precision Medicine
5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes
Subsegments:
1) By Hardware: High-Performance Computing Systems, AI-Enabled Laboratory Equipment, Data Storage Solutions
2) By Software: Drug Discovery Platforms, Predictive Analytics Tools, Natural Language Processing Solutions
3) By Services: Consulting Services, Implementation And Integration Services, Data Management And Analytics Services, Training And Support Services
Which Trends Are Influencing The Performance And Direction Of The Artificial Intelligence (AI) In Biopharmaceuticals Market?
Leading companies in artificial intelligence (AI) within the biopharmaceutical sector are concentrating on developing innovative advancements, such as AI-powered solutions for target and lead identification suites, to accelerate drug discovery and precision medicine, thus transforming life sciences organizations. These solutions for drug discovery and precision medicine involve a range of inventive approaches to developing new drugs and customizing treatments for individual patients. For example, in May 2023, Google LLC, a US-based cloud computing services provider, launched two new AI-powered tools named target and lead identification suites. These tools are designed to assist researchers in predicting and understanding the structure of proteins, a fundamental component of drug development. Additionally, this suite will help researchers ingest, store, analyze, and share vast amounts of genomic data, which is vital for precision medicine. These tools also aim to streamline the drug discovery process, reduce costs, and expedite the market entry of new treatments. By offering efficient data management, accurate protein structure predictions, and advanced genomic analysis capabilities, these tools aspire to revolutionize drug development processes and enhance patient outcomes.
Who Are The Core Companies Influencing Trends In The Artificial Intelligence (AI) In Biopharmaceuticals Market?
Major companies operating in the artificial intelligence (ai) in biopharmaceuticals market are Exscientia Limited, DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.
Access The Complete Report For Deeper Market Insights:
Which Regions Are Projected To Dominate The Artificial Intelligence (AI) In Biopharmaceuticals Market In The Coming Years?
North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (ai) in biopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Artificial Intelligence (AI) In Biopharmaceuticals Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=14251&type=smp
Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Biopharmaceuticals Market 2026, By The Business Research Company
Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026
Artificial Intelligence In Drug Discovery Market Report 2026
Artificial Intelligence Ai In Precision Medicine Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model